How NIH and NLM help during COVID-19

The James H. Shannon Building on the NIH campus in Bethesda, Maryland.

As experts at the National Institutes of Health (NIH) and across the world address public health emergencies like COVID-19, NIH is there.  

This spring, NIH and the Foundation for the NIH launched the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative. ACTIV focuses on supporting researchers and testing potential vaccines and treatments. It brings together leaders from the public and private sectors around the world. NIH is partnering on the initiative with biopharmaceutical companies, multiple U.S. federal agencies, and the European Medicines Agency.  

As part of NIH, the National Library of Medicine (NLM) is doing its part to support everyone from researchers to the general public with resources around COVID-19. 

NLM’s PubMed Central® (PMC) houses peer-reviewed biomedical and life sciences articles that include findings from clinical trials and other studies. Recently, NLM expanded access to these articles. This will ensure researchers, health care providers, text-mining databases, and the general public have the best information available to them.

Through, NLM provides access to more than 50,000 clinical trials—including trials on COVID-19—taking place around the world. Users can search by disease topic, researcher, location, and more. Additionally, NLM’s National Center for Biotechnology Information offers a data hub of genetic sequences called GenBank®. Genetic sequences are key for researchers as they work to better understand COVID-19 and develop treatments or cures.  

For the latest on NIH’s response to COVID-19, visit

← Blog